



NDA's 18-276/S-044, 21-434/S-006

SUPPLEMENT APPROVAL

Pfizer Inc.
Attention: Lisa Rysso-DeMaggio
Regulatory Associate, Worldwide Regulatory Strategy
235 East 42nd Street
New York, NY 10017-5755

Dear Ms. Rysso-DeMaggio:

Please refer to your Supplemental New Drug Applications (sNDAs) dated April 25, 2011, received April 29, 2011, submitted under section 505(b) of the Federal Food Drug, and Cosmetic Act (FDCA) for Xanax (alprazolam) tablets and Xanax XR (alprazolam) extended-release tablets.

This Changes Being Effected (CBE) supplemental new drug application provides for revisions to the labeling for Xanax (alprazolam) tablets and Xanax XR (alprazolam) extended-release tablets.

We have completed our review of these supplemental applications. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, using the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>, that is identical to the enclosed labeling and include the labeling changes proposed in any pending "Changes Being Effected" (CBE) supplements. Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for these NDAs, including pending CBE supplements, for which FDA has not yet issued an action letter, with the content of

labeling [21 CFR 314.50(l)(1)(i)] in MS Word format that includes the changes approved in this supplemental application.

LETTERS TO HEALTH CARE PROFESSIONALS

If you decide to issue a letter communicating important safety-related information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit, at least 24 hours prior to issuing the letter, an electronic copy of the letter to this NDA to the following address:

MedWatch Program
Office of Special Health Issues
Food and Drug Administration
10903 New Hampshire Ave
Building 32, Mail Stop 5353
Silver Spring, MD 20993

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Sonny Saini, Pharm.D., MBA, Regulatory Project Manager, at (301) 796-0532.

Sincerely,

{See appended electronic signature page}

Thomas Laughren, M.D.
Director
Division of Psychiatry Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

THOMAS P LAUGHREN
06/01/2011